Emtricitabine/rilpivirine/tenofovir alafenamide

Drug Profile

Emtricitabine/rilpivirine/tenofovir alafenamide

Alternative Names: FTC/RPV/TAF; Odefsey; R/F/TAF; Rilpivirine/emtricitabine/tenofovir alafenamide; Tenofovir alafenamide/rilpivirine/emtricitabine

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences; Janssen
  • Class Antiretrovirals; Deoxyribonucleosides; Nitriles; Purines; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 16 Feb 2017 Registered for HIV-1 infections (Treatment-experienced) in Canada (PO)
  • 21 Jul 2016 Efficacy and adverse events data from two phase III trials in HIV-1 infections (Treatment-experienced) released by Gilead Sciences
  • 23 Jun 2016 Registered for HIV-1 infections (In adolescents, Treatment-naive, Treatment-experienced, In adults) in Liechtenstein, Iceland, Norway, European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top